Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HROW
SellHot AirHarrow, Inc. · Healthcare · United States · $1.5B · Avg Vol: $19M/d
COMPANY DESCRIPTION
Harrow, Inc. is an ophthalmic pharmaceutical company focused on the development, production, and commercialization of a broad portfolio of branded and generic eye care products. The company leverages its vertically integrated capabilities, including sterile ophthalmic compounding, and an expanding commercial infrastructure to serve the specialized needs of the ophthalmic market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.6M | 130.2M | 199.6M | 272.3M | 45.4% | 275.6M | 350.7M | 532.5M | 39.8% |
| EPS | -0.51 | -0.75 | -0.49 | -0.14 | — | -0.99 | — | — | — |
| Shares | 29.9M | 35.2M | 35.6M | 37.2M | +24.5% | 37.5M | — | — | — |
| Debt | 112.2M | 193.2M | 228.8M | 252.0M | 30.9% | 300.7M | — | — | — |
| Equity | 27.6M | 70.8M | 69.7M | 52.4M | 23.9% | — | — | — | — |
| Op CF | 1.7M | 3.8M | -22.2M | 43.9M | 195.2% | 6.3M | — | — | — |
| Inv CF | -1.7M | -152.6M | -33.2M | -5.5M | — | — | — | — | — |
| Fin CF | 54.1M | 126.5M | 28.5M | -12.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HROW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HROW | Harrow, Inc.(you) | $1.5B | 29 | Sell |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.9B | 30 | Sell |
| GLAS | Glass House Brands Inc. | $931M | 18 | Strong Sell |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | 43 | Hold |
| VREO.CN | Vireo Growth Inc. | $552M | 33 | Sell |
| CURA.TO | Curaleaf Holdings, Inc. | $2.6B | 48 | Hold |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
| AQST | Aquestive Therapeutics, Inc. | $630M | 14 | Strong Sell |
| HIMS | Hims & Hers Health, Inc. | $6.7B | 26 | Sell |
| ORGO | Organogenesis Holdings Inc. | $224M | 29 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%